In IMPT-based proton therapy, spot size and lateral penumbra are critical to precisely deliver treatment and spare critical structures close to the target. Using Mevion’s HYPERSCAN PBS with Adaptive Aperture proton MLC, an optimal spot size and sharper penumbra can be achieved at each energy layer of the target, thus creating a more conformal treatment field than previously achievable by relying on small spot sizes alone.

In July, users who have successfully deployed Mevion’s Adaptive Aperture proton MLC in their clinical programs presented at Mevion Industry Symposium at NAPT 2020. The speakers shared the advantages they have experienced and how MLC-enhanced IMPT may further advance the treatment paradigm of proton therapy over IMRT through improved proton dose conformality.

Mevion's Senior VP of Clinical Relationships, Skip Rosenthal (PhD,) introduces the sharing sessions below. These users include Dr. Brian Baumann of Washington University, Hosang Jin (PhD) of the University of Oklahoma, and Dr. Brian Collins of MedStar Georgetown University Hospital.

Watch the symposium recordings here:

Introduction: MLC Based IMPT In Complex Cases

Skip Rosenthal, PhD

Senior VP, Clinical Relationships

Mevion Medical Systems

Comparative Effectiveness of Proton vs. Photon and the Promise of IMPT